[Clinical studies on sulbactam/cefoperazone in the field of obstetrics and gynecology].
Sulbactam (SBT), a new beta-lactamase inhibitor, in combination with cefoperazone (CPZ) to 1 to 1 was clinically studied in the field of obstetrics and gynecology. SBT/CPZ was administered to 13 subjects at a daily dose of 2 g in 2 divided dose by intravenous infusion for 4-6 days. The subjects were patients with the following infections: 2 of intrauterine infections, 5 of intrapelvic infections, 4 of adnexitis and 2 of vulvar infections. The overall clinical efficacy was good in all. Neither adverse reactions nor abnormal laboratory findings were observed in any of the cases.